Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 7/20 | 0.43 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915120 | 0.82 | DRD2 (0.52) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL25407437 | 0.78 | DRD2 (0.58) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL26288708 | 0.78 | DRD2 (0.58) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL26288599 | 0.78 | DRD2 (0.58) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL7594861 | 0.78 | SLC6A4 (0.64) | HTR3AHTR3EHTR3BADRB1HTR3D | |
| SCHEMBL9527382 | 0.78 | HTR6 (0.48) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL8911452 | 0.77 | DRD2 (0.56) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL30506635 | 0.77 | DRD2 (0.56) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL22960774 | 0.75 | HTR6 (0.45) | HTR6DRD2HTR3ADRD3HTR3E | |
| SCHEMBL15234120 | 0.75 | LMNA (0.47) | HTR6DRD2HTR3ADRD3HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150527-B1 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2011-01-19 | — | — | EP | claimed |
| EP-2150527-A2 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2010-02-10 | — | — | EP | claimed |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-01-21 | — | — | US | claimed |
| WO-2008114275-A2 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-25 | — | — | WO | claimed |
| US-8309726-B2 | Substituted piperazine compounds of formula 8 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-11-13 | — | — | US | disclosed |
| US-8309726-B2 | Substituted piperazine compounds of formula 8 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-11-13 | — | — | US | disclosed |
| EP-2150527-B1 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2011-01-19 | — | — | EP | disclosed |
| EP-2150527-A2 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2010-02-10 | — | — | EP | disclosed |
| EP-2150527-A2 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2010-02-10 | — | — | EP | disclosed |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-01-21 | — | — | US | disclosed |
| WO-2008114275-A3 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008114275-A2 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008114275-A2 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | AADAC, API5, APEH | HTR6 1959/4885DRD2 4035/4885HTR3A 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.